Aryogen Biopharma (AryoGen Pharmed) is a prominent Iranian biopharmaceutical company established in 2009, with a core focus on the research, development, production, and commercialization of biosimilars and other recombinant therapeutic proteins. The company aims to provide high-quality, affordable biologic medicines to treat a range of conditions, including cancer, autoimmune diseases, and hematological disorders. Aryogen Biopharma operates state-of-the-art facilities adhering to cGMP standards and has a significant presence in the domestic market with growing export activities to various countries in the Middle East, Asia, CIS, and Latin America. Their portfolio includes well-known biosimilars like Rituximab, Trastuzumab, and Bevacizumab, among others, contributing significantly to patient access for critical therapies.
The headquarters serves as the central hub for all company operations, including advanced research and development, cGMP-compliant manufacturing of biopharmaceuticals, quality control, and corporate administration.
The facility is situated within a specialized science and technology park, indicating access to modern infrastructure, R&D labs, and potentially collaborative opportunities. It houses sophisticated bioprocessing equipment for monoclonal antibodies and recombinant proteins.
The work culture likely emphasizes scientific excellence, innovation in bioprocesses, stringent quality adherence (cGMP), and a collaborative environment focused on bringing affordable, life-saving medicines to patients.
Its location in a dedicated pharmaceutical and technology park underscores its commitment to high-tech manufacturing and R&D, positioning it as a key player in Iran's biopharmaceutical sector and a growing exporter.
Aryogen Biopharma supports global health by exporting its biosimilar and biopharmaceutical products to multiple countries across the Middle East, Asia, the Commonwealth of Independent States (CIS) region, and Latin America. Their global functions include international sales, marketing, navigating regulatory submissions for different markets, and establishing partnerships for distribution and enhanced market access in these regions. They actively participate in international pharmaceutical exhibitions to expand their global reach.
Km 25 Karaj-Qazvin Freeway, Baharan Pharmaceutical Town, Alborz Science and Technology Park
Karaj (vicinity)
Alborz Province
Iran
Address: No. 12, 10th St., Ahmad Ghasir Ave. (Bokharest), Argentina Sq., Tehran, Iran
To maintain a strong presence in Iran's capital city, which is the commercial and governmental center, supporting domestic market penetration and stakeholder engagement.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AryoGen Pharmed' leadership includes:
AryoGen Pharmed has been backed by several prominent investors over the years, including:
Publicly available information regarding specific executive hires or exits at Aryogen Biopharma in the last 12 months is limited. The company's leadership team appears relatively stable based on their official website and recent announcements. Major changes are typically not widely publicized unless they involve very senior roles or are part of broader strategic shifts.
Discover the tools AryoGen Pharmed uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for companies like Aryogen Biopharma (aryogen.com) often utilize patterns such as [first_initial][last]@aryogen.com or [first].[last]@aryogen.com. For specific individuals, direct verification or reaching out via official channels like LinkedIn is advisable.
[first_initial][last]@aryogen.com
Format
mfarivar@aryogen.com
Example
70%
Success rate
aryogen.com (Official Website) • February 5, 2024
Aryogen Biopharma (AryoGen Pharmed) actively participated in the Arab Health 2024 exhibition in Dubai, UAE. The company presented its portfolio of biopharmaceutical products and highlighted its advancements in biosimilar development and manufacturing, aiming to expand its partnerships and presence in the MENA region....more
aryogen.com (Official Website) • August 15, 2023
Aryogen Biopharma announced that its biosimilar Pegfilgrastim (Pegagen) received market authorization in Russia. This approval marks a significant milestone for the company in expanding its international footprint and providing access to critical treatments for neutropenia in cancer patients....more
The Pharma Letter • October 10, 2022
Aryogen Biopharma received approval in Russia for its adalimumab biosimilar, AryoTrust RA, used for treating autoimmune diseases. This approval expands the company's product availability in the Russian market....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AryoGen Pharmed, are just a search away.